Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in Cancer Chemother Pharmacol

Retrieve available abstracts of 63 articles:
HTML format
Text format



Single Articles


    March 2017
  1. ZHOU J, Dong F, Cui F, Xu R, et al
    The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Mar 13. doi: 10.1007/s00280-017-3269.
    PubMed     Text format     Abstract available


  2. HATA A, Katakami N, Hattori Y, Tanaka K, et al
    Pemetrexed monotherapy for chemo-naive elderly (aged >/=80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and 003).
    Cancer Chemother Pharmacol. 2017 Mar 9. doi: 10.1007/s00280-017-3259.
    PubMed     Text format     Abstract available


  3. KASHIWABARA K, Semba H, Fujii S, Tsumura S, et al
    Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
    Cancer Chemother Pharmacol. 2017 Mar 3. doi: 10.1007/s00280-017-3261.
    PubMed     Text format     Abstract available


    February 2017
  4. IMAI H, Kuwako T, Kaira K, Masuda T, et al
    Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Feb 6. doi: 10.1007/s00280-016-3232.
    PubMed     Text format     Abstract available


    January 2017
  5. SHIMIZU T, Yonesaka K, Hayashi H, Iwasa T, et al
    Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Jan 31. doi: 10.1007/s00280-016-3231.
    PubMed     Text format     Abstract available


  6. TABCHI S, Blais N, Campeau MP, Tehfe M, et al
    Single-center comparison of multiple chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Jan 12. doi: 10.1007/s00280-016-3226.
    PubMed     Text format     Abstract available


    December 2016
  7. KAIRA K, Tomizawa Y, Imai H, Sakurai R, et al
    Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    November 2016
  8. IMAI H, Kaira K, Naruse I, Hayashi H, et al
    Successful afatinib treatment of advanced non-small-cell lung cancer patients undergoing hemodialysis.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  9. GARRETT M, Taylor T, Mould DR, Amantea MA, et al
    Lack of effect of smoking status on axitinib pharmacokinetics in patients with non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  10. ZHAO J, Ye X, Xu Y, Chen M, et al
    EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  11. FUKAE M, Shiraishi Y, Hirota T, Sasaki Y, et al
    Population pharmacokinetic-pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    September 2016
  12. ODA N, Hotta K, Yoshioka H, Kudo K, et al
    Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    August 2016
  13. KUBO T, Fujiwara K, Hotta K, Okada T, et al
    A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer: Okayama Lung Cancer Study Group 0102.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  14. ZANG H, Wang W, Fan S
    The role of microRNAs in resistance to targeted treatments of non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    July 2016
  15. MADAN A, Jones BS, Bordoni R, Saleh MN, et al
    Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patients.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  16. YAMADA K, Ichiki M, Takahashi K, Hisamatsu Y, et al
    A multicenter phase II trial of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    June 2016
  17. OKUMA Y, Hosomi Y, Takahashi S, Nakahara Y, et al
    A phase II study of nanoparticle albumin-bound paclitaxel plus carboplatin as the first-line therapy in elderly patients with previously untreated advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  18. MIZOGUCHI K, Nakamura Y, Sano K, Sato S, et al
    Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  19. MATIKAS A, Kentepozidis Nu, Ardavanis A, Vaslamatzis M, et al
    Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG).
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  20. ZOU T, Yin J, Zheng W, Xiao L, et al
    Rho GTPases: RAC1 polymorphisms affected platinum-based chemotherapy toxicity in lung cancer patients.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    April 2016
  21. SEKINE A, Satoh H, Baba T, Ikeda S, et al
    Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  22. OZAWA Y, Akahori D, Koda K, Abe T, et al
    Distinctive impact of pre-existing interstitial lung disease on the risk of chemotherapy-related lung injury in patients with lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  23. GUPTA A, Hussein Z, Hassan R, Wustner J, et al
    Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection.
    Cancer Chemother Pharmacol. 2016;77:733-43.
    PubMed     Text format     Abstract available


    March 2016
  24. KUDO K, Hotta K, Bessho A, Nogami N, et al
    Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  25. KARAYAMA M, Inui N, Kusagaya H, Suzuki S, et al
    Changes in cross-sectional area of pulmonary vessels on chest computed tomography after chemotherapy in patients with advanced non-squamous non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  26. YOSHIBA S, Jansen M, Matsushima N, Chen S, et al
    Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  27. KONTOPODIS E, Kotsakis A, Kentepozidis N, Syrigos K, et al
    A phase II, open-label trial of bortezomib (VELCADE) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  28. YOSHIMURA Y, Kurasawa M, Yorozu K, Puig O, et al
    Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.
    Cancer Chemother Pharmacol. 2016;77:623-8.
    PubMed     Text format     Abstract available


  29. LUKE JJ, LoRusso P, Shapiro GI, Krivoshik A, et al
    ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumors.
    Cancer Chemother Pharmacol. 2016;77:549-58.
    PubMed     Text format     Abstract available


    February 2016
  30. TRAFALIS DT, Alifieris C, Stathopoulos GP, Sitaras N, et al
    Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  31. ZHANG Q, Sun T, Kang P, Qian K, et al
    Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    January 2016
  32. TAKAGI Y, Hosomi Y, Nagamata M, Watanabe K, et al
    Phase II study of oral vitamin B supplementation as an alternative to intramuscular injection for patients with non-small cell lung cancer undergoing pemetrexed therapy.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  33. HEO SJ, Jung I, Lee CK, Kim JH, et al
    A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  34. RAJAGOPALAN P, Alahmari KA, Elbessoumy AA, Balasubramaniam M, et al
    Biological evaluation of 2-arylidene-4, 7-dimethyl indan-1-one (FXY-1): a novel Akt inhibitor with potent activity in lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  35. STROH M, Green M, Cha E, Zhang N, et al
    Meta-analysis of published efficacy and safety data for docetaxel in second-line treatment of patients with advanced non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    December 2015
  36. KUMAR R, Lu SK, Minchom A, Sharp A, et al
    A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


    November 2015
  37. ARBITRIO M, Di Martino MT, Barbieri V, Agapito G, et al
    Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


  38. DAGA H, Takeda K, Okada H, Miyazaki M, et al
    Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


  39. TOLCHER AW, LoRusso P, Arzt J, Busman TA, et al
    Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.
    Cancer Chemother Pharmacol. 2015;76:1025-32.
    PubMed     Text format     Abstract available


  40. MORGAN RJ, Synold TW, Longmate JA, Quinn DI, et al
    Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.
    Cancer Chemother Pharmacol. 2015;76:897-907.
    PubMed     Text format     Abstract available


    October 2015
  41. MIZUGAKI H, Yamamoto N, Nokihara H, Fujiwara Y, et al
    A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC).
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


    September 2015
  42. SHINKE H, Masuda S, Togashi Y, Ikemi Y, et al
    Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


  43. ALLENDORF DJ, Bordoni RE, Grant SC, Saleh MN, et al
    Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC).
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


  44. LEE HS, Lee YG, Koo DH, Oh S, et al
    Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


  45. OTSUKA K, Hata A, Takeshita J, Okuda C, et al
    EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


  46. MLAK R, Krawczyk P, Ciesielka M, Homa I, et al
    Predictive value of STMN1 gene promoter polymorphism (-2166T>C) in patients with advanced NSCLC treated with the combination of platinum compounds and vinorelbine.
    Cancer Chemother Pharmacol. 2015;76:621-9.
    PubMed     Text format     Abstract available


    August 2015
  47. FANG L, Sun X, Song Y, Zhang Y, et al
    Whole-brain radiation fails to boost intracerebral gefitinib concentration in patients with brain metastatic non-small cell lung cancer: a self-controlled, pilot study.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


  48. SHUKUYA T, Ko R, Mori K, Kato M, et al
    Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


  49. KUWAKO T, Imai H, Masuda T, Miura Y, et al
    First-line gefitinib treatment in elderly patients (aged >/=75 years) with non-small cell lung cancer harboring EGFR mutations.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


  50. MOTONAGA M, Yamamoto N, Makino Y, Ando-Makihara R, et al
    Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


    July 2015
  51. FAN Y, Huang Z, Fang L, Miao L, et al
    A phase II study of icotinib and whole-brain radiotherapy in Chinese patients with brain metastases from non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


  52. ENOMOTO Y, Inui N, Imokawa S, Karayama M, et al
    Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


  53. CHU MP, McCaw L, Stretch C, Butts C, et al
    Development of a new equation to estimate creatinine clearance in cancer patients.
    Cancer Chemother Pharmacol. 2015;76:117-24.
    PubMed     Text format     Abstract available


    June 2015
  54. LI J, Chen R, Ji M, Zou SL, et al
    Cisplatin-based chronotherapy for advanced non-small cell lung cancer patients: a randomized controlled study and its pharmacokinetics analysis.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


  55. WU H, Fan F, Liu Z, Shen C, et al
    Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


  56. KUDO K, Hotta K, Ichihara E, Yoshioka H, et al
    Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


  57. KAWAMURA T, Hata A, Takeshita J, Fujita S, et al
    High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs.
    Cancer Chemother Pharmacol. 2015;75:1261-6.
    PubMed     Text format     Abstract available


    May 2015
  58. FARHAT FS, Ghosn MG, Kattan JG
    Oral vinorelbine plus cisplatin followed by maintenance oral vinorelbine as first-line treatment for advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


  59. INOUE Y, Inui N, Asada K, Karayama M, et al
    Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


  60. WANG LR, He LJ, Wang Y, Li YY, et al
    Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


  61. KATSUYA Y, Fujiwara Y, Sunami K, Utsumi H, et al
    Comparison of the pharmacokinetics of erlotinib administered in complete fasting and 2 h after a meal in patients with lung cancer.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


  62. WATANABE N, Niho S, Kirita K, Umemura S, et al
    Second-line docetaxel for patients with platinum-refractory advanced non-small cell lung cancer and interstitial pneumonia.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


    April 2015
  63. PILON JL, Clausen DJ, Hansen RJ, Lunghofer PJ, et al
    Comparative pharmacokinetic properties and antitumor activity of the marine HDACi Largazole and Largazole peptide isostere.
    Cancer Chemother Pharmacol. 2015;75:671-82.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: